GlaxoSmithKline  (GSK - Get Report) is considering buying out partner Novartis'  (NVS - Get Report)  stake in its consumer healthcare joint venture in a deal that could be worth about $10 billion as Glaxo looks to expand its consumer healthcare business, the Sunday Times reported. 

Novartis' stake in the business is 36.5%. The Swiss drugmaker could use the funds from the sale to purchase rival Astrazeneca  (AZN - Get Report) , according to the Times

Novartis and GlaxoSmithKline created a joint consumer healthcare business in 2014 as part of a larger asset swap. Glaxo shares were down 0.3% premarket Monday while Novartis shares were down 0.16%. 

Jim Cramer and Real Money columnists discuss the latest from President Donald Trump and the GOP efforts to repeal and replace the Affordable Care Act. See which stocks they are discussing and get hisinsights or analysis with a free trial subscription to Real Money.

Read More Trending Articles: